The CLL treatment resulted in a 23-fold reduction of CD11b+ CD115+ cells (monocytes) and a 6-fold reduction of CD11b+ F4/80+-expressing macrophages in the blood and spleen, respectively. The gene discussed is CSF1R; the disease is B-cell chronic lymphocytic leukemia.